• 

  May 6, 2025

  VivoSim Labs Introduces NAMkind Platform for Human-Based Drug Testing Models

  Ricky Solorzano

• 

  April 27, 2025

  Cellino and Karis Bio Partner to Advance Personalized iPSC Therapies for Peripheral Artery Disease

  Ricky Solorzano

• 

  April 27, 2025

  Vivodyne CEO Discusses FDA’s Move Away from Animal Testing and the Future of Humanized Drug Development

  Ricky Solorzano

• 

  April 27, 2025

  Organovo Rebrands as VivoSim Labs to Advance 3D Bioprinting Technology

  Ricky Solorzano

• 

  April 16, 2025

  Cellbricks Reports Preclinical Success with Bioprinted Tissue in Mice

  Ricky Solorzano

• 

  April 16, 2025

  FluidForm Bio Launches $1.24M Crowdfunding Round to Advance Bioprinted Diabetes Therapy

  Ricky Solorzano

• 

  April 8, 2025

  Xylyx Bio Secures $1.125 Million to Advance Innovations in Xenogeneic Cross-Circulation Transplant Organs

  Ricky Solorzano

• 

  April 3, 2025

  Organovo Sells FXR Drug Program to Eli Lilly in Strategic Deal to Advance IBD Therapies

  Ricky Solorzano

• 

  April 3, 2025

  LyGenesis Receives Green Light to Advance Organ Regeneration Trial

  Ricky Solorzano

• 

  March 18, 2025

  How Cellino and Matricelf are Advancing Neural Tissue Engineering

  Ricky Solorzano